Neoantigen cancer vaccines for gastrointestinal tumors: opportunities and challenges

Abstract

Gastrointestinal tumors are characterized by high global incidence and mortality rates. Although immune checkpoint inhibitors (ICIs) have achieved breakthroughs in some of these cancers, their overall response rate remains low. Neoantigen cancer vaccines have emerged as a promising new strategy for immunotherapy in gastrointestinal tumors due to their high specificity and strong immunogenicity. These vaccines effectively activate specific T-cell immunity and can produce synergistic effects when combined with ICIs. Various vaccine platforms offer distinct advantages, and clinical trials have shown encouraging potential in inducing immune responses and extending progression-free survival. Meanwhile, current challenges and future directions cannot be ignored. Key challenges primarily involve the accuracy of neoantigen prediction, tumor heterogeneity, and optimal treatment timing. Future directions include artificial intelligence (AI)-assisted multi-omics screening, the development of universal vaccines, optimization of novel delivery systems, and multimodal combination strategies. These advances are expected to promote the application of neoantigen cancer vaccines in postoperative recurrence prevention and early-stage treatment, ultimately moving toward personalized precision immunotherapy. This article systematically reviews the clinical progress and prospects of neoantigen cancer vaccines in treating gastrointestinal tumors, aiming to provide insights for immunotherapy in this field and offer new perspectives for further optimization of such vaccines.

Keywords

neoantigen cancer vaccine / gastrointestinal tumors / tumor neoantigen / immunotherapy / clinical research

References

[1] Lee JB , Kim HR , Ha SJ . Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy. Immune Netw 2022; 22(1): e2

[2] Korman AJ , Garrett-Thomson SC , Lonberg N . The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov 2022; 21(7): 509–528

[3] Pirš B , Škof E , Smrkolj V , Smrkolj Š . Overview of immune checkpoint inhibitors in gynecological cancer treatment. Cancers (Basel) 2022; 14(3): 631

[4] Liu N , Xiao X , Zhang Z , Mao C , Wan M , Shen J . Advances in cancer vaccine research. ACS Biomater Sci Eng 2023; 9(11): 5999–6023

[5] Pail O , Lin MJ , Anagnostou T , Brown BD , Brody JD . Cancer vaccines and the future of immunotherapy. Lancet 2025; 406(10499): 189–202

[6] Lee J , Uy BR , Liau LM . Brain tumor vaccines. Neurosurg Clin N Am 2021; 32(2): 225–234

[7] Huang L , Liu Z , Wu C , Lin J , Liu N . Magnetic nanoparticles enhance the cellular immune response of dendritic cell tumor vaccines by realizing the cytoplasmic delivery of tumor antigens. Bioeng Transl Med 2023; 8(2): e10400

[8] Ragone C , Manolio C , Cavalluzzo B , Mauriello A , Tornesello ML , Buonaguro FM , Castiglione F , Vitagliano L , Iaccarino E , Ruvo M , Tagliamonte M , Buonaguro L . Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs). J Immunother Cancer 2021; 9(5): e002694

[9] Li N , Qin H , Zhu F , Ding H , Chen Y , Lin Y , Deng R , Ma T , Lv Y , Xiong C , Li R , Wei Y , Shi J , Chen H , Zhao Y , Zhou G , Guo H , Lv M , Lin Y , Han B , Nie G , Zhao R . Potent prophylactic cancer vaccines harnessing surface antigens shared by tumour cells and induced pluripotent stem cells. Nat Biomed Eng 2025; 9(2): 215–233

[10] Blass E , Ott PA . Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol 2021; 18(4): 215–229

[11] Zaidi N , Jaffee EM , Yarchoan M . Recent advances in therapeutic cancer vaccines. Nat Rev Cancer 2025; 25(7): 517–533

[12] Katsikis PD , Ishii KJ , Schliehe C . Challenges in developing personalized neoantigen cancer vaccines. Nat Rev Immunol 2024; 24(3): 213–227

[13] Fang X , Guo Z , Liang J , Wen J , Liu Y , Guan X , Li H . Neoantigens and their potential applications in tumor immunotherapy. Oncol Lett 2022; 23(3): 88

[14] Ebrahimi N , Akbari M , Ghanaatian M , Roozbahani Moghaddam P , Adelian S , Borjian Boroujeni M , Yazdani E , Ahmadi A , Hamblin MR . Development of neoantigens: from identification in cancer cells to application in cancer vaccines. Expert Rev Vaccines 2022; 21(7): 941–955

[15] Ma W , Pham B , Li T . Cancer neoantigens as potential targets for immunotherapy. Clin Exp Metastasis 2022; 39(1): 51–60

[16] Li M , Cao S , Xu RH . Global trends and epidemiological shifts in gastrointestinal cancers: insights from the past four decades. Cancer Commun (Lond) 2025; 45(7): 774–788

[17] Bu J , Cui M , Zhang Y , Lu Y , Zhu X , Peng F , Zhang H . Cancer stem cells in human gastrointestinal and hepatic cancers. MedComm 2025; 6(12): e70513

[18] Xie W , Yang T , Zuo J , Ma Z , Yu W , Hu Z , Song Z . Chinese and global burdens of gastrointestinal cancers from 1990 to 2019. Front Public Health 2022; 10: 941284

[19] Tieniber AD , Perez JE , Hanna AN , DeMatteo RP. . Immunotherapy for GI malignancies, ready for prime time?. Ann Surg Oncol 2023; 30(3): 1787–1793

[20] Wang DK , Zuo Q , He QY , Li B . Targeted immunotherapies in gastrointestinal cancer: from molecular mechanisms to implications. Front Immunol 2021; 12: 705999

[21] Peshin S , Bashir F , Kodali NA , Dharia A , Zaiter S , Singal S , Moka N . Immunotherapy in GI cancers: lessons from key trials and future clinical applications. Antibodies (Basel) 2025; 14(3): 58

[22] Zhou C , Zhang J . Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects. Front Med 2019; 13(1): 12–23

[23] Chénard-Poirier M , Smyth EC . Immune checkpoint inhibitors in the treatment of gastroesophageal cancer. Drugs 2019; 79(1): 1–10

[24] Chen X , Wu W , Wei W , Zou L . Immune checkpoint inhibitors in peripheral T-cell lymphoma. Front Pharmacol 2022; 13: 869488

[25] Zeng Z , Yang B , Liao Z . Biomarkers in immunotherapy-based precision treatments of digestive system tumors. Front Oncol 2021; 11: 650481

[26] Takei S , Kawazoe A , Shitara K . The new era of immunotherapy in gastric cancer. Cancers (Basel) 2022; 14(4): 1054

[27] Li S , Yu W , Xie F , Luo H , Liu Z , Lv W , Shi D , Yu D , Gao P , Chen C , Wei M , Zhou W , Wang J , Zhao Z , Dai X , Xu Q , Zhang X , Huang M , Huang K , Wang J , Li J , Sheng L , Liu L . Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nat Commun 2023; 14(1): 8

[28] Vickram S , Infant SS , Manikandan S , Jenila Rani D , Mathan Muthu CM , Chopra H . Immune biomarkers and predictive signatures in gastric cancer: optimizing immunotherapy responses. Pathol Res Pract 2025; 265: 155743

[29] Childs A , Aidoo-Micah G , Maini MK , Meyer T . Immunotherapy for hepatocellular carcinoma. JHEP Rep Innov Hepatol 2024; 6(10): 101130

[30] Finn RS , Qin S , Ikeda M , Galle PR , Ducreux M , Kim TY , Kudo M , Breder V , Merle P , Kaseb AO , Li D , Verret W , Xu DZ , Hernandez S , Liu J , Huang C , Mulla S , Wang Y , Lim HY , Zhu AX , Cheng AL . Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020; 382(20): 1894–1905

[31] Overman MJ , Lonardi S , Wong KYM , Lenz HJ , Gelsomino F , Aglietta M , Morse MA , Van Cutsem E , McDermott R , Hill A , Sawyer MB , Hendlisz A , Neyns B , Svrcek M , Moss RA , Ledeine JM , Cao ZA , Kamble S , Kopetz S , André T . Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 2018; 36(8): 773–779

[32] Petrelli F , Dottorini L , Zaniboni A , Celotti A , Iaculli A . Immune checkpoint inhibitors for dMMR/MSI localized rectal cancer: a systematic review of treatment strategies. Crit Rev Oncol Hematol 2025; 215: 104921

[33] Wei J , Zhang P , Hu Q , Cheng X , Shen C , Chen Z , Zhuang W , Yin Y , Zhang B , Gou H , Yang K , Bi F , Liu M . Nab-paclitaxel combined with cadonilimab (AK104) as second-line treatment for advanced gastric cancer: protocol for a phase II prospective, multicenter, single-arm clinical trial. Front Immunol 2025; 16: 1519545

[34] Kou L , Wen Q , Xie X , Chen X , Li J , Li Y . Adverse events of immune checkpoint inhibitors for patients with digestive system cancers: a systematic review and meta-analysis. Front Immunol 2022; 13: 1013186

[35] Khleif SN , Gupta S . Cancer vaccines as enablers of immunotherapy. Nat Immunol 2025; 26(11): 1877–1889

[36] Wu DW , Jia SP , Xing SJ , Ma HL , Wang X , Tang QY , Li ZW , Wu Q , Bai M , Zhang XY , Fu XF , Jia MM , Tang Y , Chen L , Li N . Personalized neoantigen cancer vaccines: current progression, challenges and a bright future. Clin Exp Med 2024; 24(1): 229

[37] Zhang Z , Yao S , Wang Y , Luo K , Amiji M , Anderson KC . Cancer vaccines: discovery, development, and challenges for clinical translation. Biomaterials 2026; 325: 123615

[38] Wang Q , Wang Z , Sun X , Jiang Q , Sun B , He Z , Zhang S , Luo C , Sun J . Lymph node-targeting nanovaccines for cancer immunotherapy. J Control Release 2022; 351: 102–122

[39] Zuo Q , Li T , Huang L , Liu Z , Xue W . Macro-microporous ZIF-8 MOF complexed with lysosomal pH-adjusting hexadecylsulfonylfluoride as tumor vaccine delivery systems for improving anti-tumor cellular immunity. Biomater Sci 2023; 11(14): 5025–5045

[40] Graciotti M , Kandalaft LE . Vaccines for cancer prevention: exploring opportunities and navigating challenges. Nat Rev Drug Discov 2025; 24(2): 134–150

[41] Han X , Gao Z , Cheng Y , Wu S , Chen J , Zhang W . A therapeutic DNA vaccine targeting HPV16 E7 in combination with anti-PD-1/PD-L1 enhanced tumor regression and cytotoxic immune responses. Int J Mol Sci 2023; 24(20): 15469

[42] Verma C , Pawar VA , Srivastava S , Tyagi A , Kaushik G , Shukla SK , Kumar V . Cancer vaccines in the immunotherapy era: promise and potential. Vaccines (Basel) 2023; 11(12): 1783

[43] Xie N , Shen G , Gao W , Huang Z , Huang C , Fu L . Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther 2023; 8(1): 9

[44] Shang S , Zhao Y , Qian K , Qin Y , Zhang X , Li T , Shan L , Wei M , Xi J , Tang B . The role of neoantigens in tumor immunotherapy. Biomed Pharmacother 2022; 151: 113118

[45] Zhao X , Wei L , Zhang X . Computational methods and data resources for predicting tumor neoantigens. Brief Bioinform 2025; 26(4): bbaf302

[46] Patel RB , Ye M , Carlson PM , Jaquish A , Zangl L , Ma B , Wang Y , Arthur I , Xie R , Brown RJ , Wang X , Sriramaneni R , Kim K , Gong S , Morris ZS . Development of an in situ cancer vaccine via combinational radiation and bacterial-membrane-coated nanoparticles. Adv Mater 2019; 31(43): 1902626

[47] Lu Z , Zhu W , Liu X . Application prospects of tumor vaccines for pancreatic cancer: from TAAs to TSAs and combination strategies. Semin Oncol 2025; 52(5): 152399

[48] Pao SC , Chu MT , Hung SI . Therapeutic vaccines targeting neoantigens to induce T-cell immunity against cancers. Pharmaceutics 2022; 14(4): 867

[49] Zhang X , Goedegebuure SP , Chen MY , Mishra R , Zhang F , Yu YY , Singhal K , Li L , Gao F , Myers NB , Vickery T , Hundal J , McLellan MD , Sturmoski MA , Kim SW , Chen I , Davidson JT 4th , Sankpal NV , Myles S , Suresh R , Ma CX , Foluso A , Wang-Gillam A , Davies S , Hagemann IS , Mardis ER , Griffith O , Griffith M , Miller CA , Hansen TH , Fleming TP , Schreiber RD , Gillanders WE . Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients. Genome Med 2024; 16(1): 131

[50] Xie N , Shen G , Huang C , Zhu H . Neoantigen-driven personalized tumor therapy: an update from discovery to clinical application. Chin Med J (Engl) 2025; 138(17): 2057–2090

[51] Zhu Y , Liu J . The Role of neoantigens in cancer immunotherapy. Front Oncol 2021; 11: 682325

[52] Lang F , Schrörs B , Löwer M , Türeci Ö , Sahin U . Identification of neoantigens for individualized therapeutic cancer vaccines. Nat Rev Drug Discov 2022; 21(4): 261–282

[53] Xia H , McMichael J , Becker-Hapak M , Onyeador OC , Buchli R , McClain E , Pence P , Supabphol S , Richters MM , Basu A , Ramirez CA , Puig-Saus C , Cotto KC , Freshour SL , Hundal J , Kiwala S , Goedegebuure SP , Johanns TM , Dunn GP , Ribas A , Miller CA , Gillanders WE , Fehniger TA , Griffith OL , Griffith M . Computational prediction of MHC anchor locations guides neoantigen identification and prioritization. Sci Immunol 2023; 8(82): eabg2200

[54] Han XJ , Ma XL , Yang L , Wei YQ , Peng Y , Wei XW . Progress in neoantigen targeted cancer immunotherapies. Front Cell Dev Biol 2020; 8: 728

[55] Mørk SK , Kadivar M , Bol KF , Draghi A , Westergaard MCW , Skadborg SK , Overgaard N , Sørensen AB , Rasmussen IS , Andreasen LV , Yde CW , Trolle T , Garde C , Friis-Nielsen J , Nørgaard N , Christensen D , Kringelum JV , Donia M , Hadrup SR , Svane IM . Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma. OncoImmunology 2022; 11(1): 2023255

[56] Liu Z , Lv J , Dang Q , Liu L , Weng S , Wang L , Zhou Z , Kong Y , Li H , Han Y , Han X . Engineering neoantigen vaccines to improve cancer personalized immunotherapy. Int J Biol Sci 2022; 18(15): 5607–5623

[57] Alexandrov LB , Nik-Zainal S , Wedge DC , Aparicio SA , Behjati S , Biankin AV , Bignell GR , Bolli N , Borg A , Børresen-Dale AL , Boyault S , Burkhardt B , Butler AP , Caldas C , Davies HR , Desmedt C , Eils R , Eyfjörd JE , Foekens JA , Greaves M , Hosoda F , Hutter B , Ilicic T , Imbeaud S , Imielinski M , Jäger N , Jones DT , Jones D , Knappskog S , Kool M , Lakhani SR , López-Otín C , Martin S , Munshi NC , Nakamura H , Northcott PA , Pajic M , Papaemmanuil E , Paradiso A , Pearson JV , Puente XS , Raine K , Ramakrishna M , Richardson AL , Richter J , Rosenstiel P , Schlesner M , Schumacher TN , Span PN , Teague JW , Totoki Y , Tutt AN , Valdés-Mas R , van Buuren MM , van ’t Veer L , Vincent-Salomon A , Waddell N , Yates LR , Australian Pancreatic Cancer Genome Initiative , ICGC Breast Cancer Consortium , ICGC MMML-Seq Consortium , ICGC PedBrain , Zucman-Rossi J , Futreal PA , McDermott U , Lichter P , Meyerson M , Grimmond SM , Siebert R , Campo E , Shibata T , Pfister SM , Campbell PJ , Stratton MR . Signatures of mutational processes in human cancer. Nature 2013; 500(7463): 415–421

[58] Schumacher TN , Schreiber RD . Neoantigens in cancer immunotherapy. Science 2015; 348(6230): 69–74

[59] Chen F , Wang F , Xu RH . Updates on immunotherapy of gastrointestinal cancers and practical challenges. Chin J Gastrointest Surg (Zhonghua Wei Chang Wai Ke Za Zhi) 2024; 27(1): 24–34

[60] Zhao Q , Wang F , Chen YX , Chen S , Yao YC , Zeng ZL , Jiang TJ , Wang YN , Wu CY , Jing Y , Huang YS , Zhang J , Wang ZX , He MM , Pu HY , Mai ZJ , Wu QN , Long R , Zhang X , Huang T , Xu M , Qiu MZ , Luo HY , Li YH , Zhang DS , Jia WH , Chen G , Ding PR , Li LR , Lu ZH , Pan ZZ , Xu RH . Comprehensive profiling of 1015 patients’ exomes reveals genomic-clinical associations in colorectal cancer. Nat Commun 2022; 13(1): 2342

[61] Kwok DW , Stevers NO , Etxeberria I , Nejo T , Cove MC , Chen LH , Jung J , Okada K , Lakshmanachetty S , Gallus M , Barpanda A , Hong C , Chan GKL , Liu J , Wu SH , Ramos E , Yamamichi A , Watchmaker PB , Ogino H , Saijo A , Du A , Grishanina NR , Woo J , Diaz A , Hervey-Jumper SL , Chang SM , Phillips JJ , Wiita AP , Klebanoff CA , Costello JF , Okada H . Tumour-wide RNA splicing aberrations generate actionable public neoantigens. Nature 2025; 639(8054): 463–473

[62] Liu T , Tan J , Wu M , Fan W , Wei J , Zhu B , Guo J , Wang S , Zhou P , Zhang H , Shi L , Li J . High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39⁺CD8⁺ T cells. Gut 2021; 70(10): 1965–1977

[63] Rojas LA , Sethna Z , Soares KC , Olcese C , Pang N , Patterson E , Lihm J , Ceglia N , Guasp P , Chu A , Yu R , Chandra AK , Waters T , Ruan J , Amisaki M , Zebboudj A , Odgerel Z , Payne G , Derhovanessian E , Müller F , Rhee I , Yadav M , Dobrin A , Sadelain M , Łuksza M , Cohen N , Tang L , Basturk O , Gönen M , Katz S , Do RK , Epstein AS , Momtaz P , Park W , Sugarman R , Varghese AM , Won E , Desai A , Wei AC , D’Angelica MI , Kingham TP , Mellman I , Merghoub T , Wolchok JD , Sahin U , Türeci Ö , Greenbaum BD , Jarnagin WR , Drebin J , O’Reilly EM , Balachandran VP . Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 2023; 618(7963): 144–150

[64] Sethna Z , Guasp P , Reiche C , Milighetti M , Ceglia N , Patterson E , Lihm J , Payne G , Lyudovyk O , Rojas LA , Pang N , Ohmoto A , Amisaki M , Zebboudj A , Odgerel Z , Bruno EM , Zhang SL , Cheng C , Elhanati Y , Derhovanessian E , Manning L , Müller F , Rhee I , Yadav M , Merghoub T , Wolchok JD , Basturk O , Gönen M , Epstein AS , Momtaz P , Park W , Sugarman R , Varghese AM , Won E , Desai A , Wei AC , D’Angelica MI , Kingham TP , Soares KC , Jarnagin WR , Drebin J , O’Reilly EM , Mellman I , Sahin U , Türeci Ö , Greenbaum BD , Balachandran VP . RNA neoantigen vaccines prime long-lived CD8⁺ T cells in pancreatic cancer. Nature 2025; 639(8056): 1042–1051

[65] Borden ES , Buetow KH , Wilson MA , Hastings KT . Cancer neoantigens: challenges and future directions for prediction, prioritization, and validation. Front Oncol 2022; 12: 836821

[66] Niemi JVL , Sokolov AV , Schiöth HB . Neoantigen vaccines: clinical trials, classes, indications, adjuvants and combinatorial treatments. Cancers (Basel) 2022; 14(20): 5163

[67] Saxena M , van der Burg SH , Melief CJM , Bhardwaj N . Therapeutic cancer vaccines. Nat Rev Cancer 2021; 21(6): 360–378

[68] Cao T , Zhang W , Wang Q , Wang C , Ma W , Zhang C , Ge M , Tian M , Yu J , Jiao A , Wang L , Liu M , Wang P , Guo Z , Zhou Y , Chen S , Yin W , Yi J , Guo H , Han H , Zhang B , Wu K , Fan D , Wang X , Nie Y , Lu Y , Zhao X. . Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8⁺ T cells.. Cell 2024; 187(9): 2288–304

[69] Lu T , Park S , Han Y , Wang Y , Hubert SM , Futreal PA , Wistuba I , Heymach JV , Reuben A , Zhang J , Wang T . Netie: inferring the evolution of neoantigen-T cell interactions in tumors. Nat Methods 2022; 19(11): 1480–1489

[70] Aguilar-Gurrieri C , Barajas A , Rovirosa C , Ortiz R , Urrea V , de la Iglesia N , Clotet B , Blanco J , Carrillo J . Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines. Cancer Immunol Immunother 2023; 72(7): 2113–2125

[71] Dagotto G , Colarusso A , Patio RC , Li D , Anioke T , Giffin V , Guan R , Anand T , Mbiwan E , Aid M , Barouch D . Adenoviral-vectored neoantigen vaccine augments hyperexpanded CD8⁺ T cell control of tumor challenge in mice. J Immunother Cancer 2024; 12(12): e009644

[72] Hofer T , Rossi M , Carboni S , Di Berardino Besson W , von Laer D , Wollmann G , Derouazi M , Santiago-Raber ML . Heterologous prime-boost vaccination with a peptide-based vaccine and viral vector reshapes dendritic cell, CD4⁺ and CD8⁺ T cell phenotypes to improve the antitumor therapeutic effect. Cancers (Basel) 2021; 13(23): 6107

[73] Parveen A , Elkordy AA . Brief insights into mRNA vaccines: their successful production and nanoformulation for effective response against COVID-19 and their potential success for influenza A and B. Pathogens 2024; 13(6): 500

[74] Liu Y , Ye Q . Nucleic acid vaccines against SARS-CoV-2. Vaccines (Basel) 2022; 10(11): 1849

[75] Pollard C , Rejman J , De Haes W , Verrier B , Van Gulck E , Naessens T , De Smedt S , Bogaert P , Grooten J , Vanham G , De Koker S . Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther 2013; 21(1): 251–259

[76] Hou X , Zaks T , Langer R , Dong Y . Lipid nanoparticles for mRNA delivery. Nat Rev Mater 2021; 6(12): 1078–1094

[77] Zhang A , Ji Q , Sheng X , Wu H . mRNA vaccine in gastrointestinal tumors: immunomodulatory effects and immunotherapy. Biomed Pharmacother 2023; 166: 115361

[78] Oğuz F , Atmaca H . mRNA as a therapeutics: understanding mRNA vaccines. Adv Pharm Bull 2022; 12(2): 274–282

[79] Cheng F , Wang Y , Bai Y , Liang Z , Mao Q , Liu D , Wu X , Xu M . Research advances on the stability of mRNA vaccines. Viruses 2023; 15(3): 668

[80] Kamigaki T , Takimoto R , Okada S , Ibe H , Oguma E , Goto S . Personalized dendritic-cell-based vaccines targeting cancer neoantigens. Anticancer Res 2024; 44(9): 3713–3724

[81] Zhang W , Guan J , Wang W , Chen G , Fan L , Lu Z . Neoantigen-specific mRNA/DC vaccines for effective anticancer immunotherapy. Genes Immun 2024; 25(6): 514–524

[82] Weber JS , Carlino MS , Khattak A , Meniawy T , Ansstas G , Taylor MH , Kim KB , McKean M , Long GV , Sullivan RJ , Faries M , Tran TT , Cowey CL , Pecora A , Shaheen M , Segar J , Medina T , Atkinson V , Gibney GT , Luke JJ , Thomas S , Buchbinder EI , Healy JA , Huang M , Morrissey M , Feldman I , Sehgal V , Robert-Tissot C , Hou P , Zhu L , Brown M , Aanur P , Meehan RS , Zaks T . Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 2024; 403(10427): 632–644

[83] Wang Y . Advances in cancer immunotherapy and future directions in personalized medicine. Open Life Sci 2025; 20(1): 20251179

[84] Hong W , Liao X , Xia C , Li G . Research progress on neoadjuvant immunotherapy in esophageal squamous cell carcinoma. Am Surg 2026; 92(2): 550–559

[85] Shapiro J , van Lanschot JJB , Hulshof M , van Hagen P , van Berge Henegouwen MI , Wijnhoven BPL , van Laarhoven HWM , Nieuwenhuijzen GAP , Hospers GAP , Bonenkamp JJ , Cuesta MA , Blaisse RJB , Busch ORC , Ten Kate FJW , Creemers GM , Punt CJA , Plukker JTM , Verheul HMW , Bilgen EJS , van Dekken H , van der Sangen MJC , Rozema T , Biermann K , Beukema JC , Piet AHM , van Rij CM , Reinders JG , Tilanus HW , Steyerberg EW , van der Gaast A . Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015; 16(9): 1090–1098

[86] Demarest CT , Chang AC . The landmark series: multimodal therapy for esophageal cancer. Ann Surg Oncol 2021; 28(6): 3375–3382

[87] Ni Q , Zhang F , Liu Y , Wang Z , Yu G , Liang B , Niu G , Su T , Zhu G , Lu G , Zhang L , Chen X . A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer. Sci Adv 2020; 6(12): eaaw6071

[88] Chen Y , Shi H , Hu Y , Yuan Y , Yang Y , Xu H , Yang L , Ding Z. . Safety and feasibility of personalized neoantigen DC vaccines in postoperative esophagus squamous cell carcinoma: a phase 1b trial. Cancer Res 2024; 84(Suppl 6): 4108

[89] Wang B , Peng X , Li J , Wang Y , Chen L , Wu M , Zhang Y , Wang W , Feng D , Tang S , Zhang L , Zhan X . Personalized mRNA vaccine combined with PD-1 inhibitor therapy in a patient with advanced esophageal squamous cell carcinoma. Am J Cancer Res 2024; 14(8): 3896–3904

[90] Yan X , Lei L , Li H , Cao M , Yang F , He S , Zhang S , Teng Y , Li Q , Xia C , Chen W . Stomach cancer burden in China: epidemiology and prevention. Chin J Cancer Res 2023; 35(2): 81–91

[91] Entezam M , Sanaei MJ , Mirzaei Y , Mer AH , Abdollahpour-Alitappeh M , Azadegan-Dehkordi F , Bagheri N . Current progress and challenges of immunotherapy in gastric cancer: a focus on CAR-T cells therapeutic approach. Life Sci 2023; 318: 121459

[92] Bang YJ , Kim YW , Yang HK , Chung HC , Park YK , Lee KH , Lee KW , Kim YH , Noh SI , Cho JY , Mok YJ , Kim YH , Ji J , Yeh TS , Button P , Sirzén F , Noh SH . Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012; 379(9813): 315–321

[93] Liu Q , Chu Y , Shao J , Qian H , Yang J , Sha H , Cen L , Tian M , Xu Q , Chen F , Yang Y , Wang W , Wang K , Yu L , Wei J , Liu B . Benefits of an immunogenic personalized neoantigen nanovaccine in patients with high-risk gastric/gastroesophageal junction cancer. Adv Sci (Weinh) 2023; 10(1): 2203298

[94] Lopez J , Powles T , Braiteh F , Siu LL , LoRusso P , Friedman CF , Balmanoukian AS , Gordon M , Yachnin J , Rottey S , Karydis I , Fisher GA , Schmidt M , Schuler M , Sullivan RJ , Burris HA , Galvao V , Henick BS , Dirix L , Jaeger D , Ott PA , Wong KM , Jerusalem G , Schiza A , Fong L , Steeghs N , Leidner RS , Rittmeyer A , Laurie SA , Gort E , Aljumaily R , Melero I , Sabado RL , Rhee I , Mancuso MR , Muller L , Fine GD , Yadav M , Kim L , Leveque VJP , Robert A , Darwish M , Qi T , Zhu J , Zhang J , Twomey P , Rao GK , Low DW , Petry C , Lo AA , Schartner JM , Delamarre L , Mellman I , Löwer M , Müller F , Derhovanessian E , Cortini A , Manning L , Maurus D , Brachtendorf S , Lörks V , Omokoko T , Godehardt E , Becker D , Hawner C , Wallrapp C , Albrecht C , Kröner C , Tadmor AD , Diekmann J , Vormehr M , Jork A , Paruzynski A , Lang M , Blake J , Hennig O , Kuhn AN , Sahin U , Türeci Ö , Camidge DR . Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nat Med 2025; 31(1): 152–164

[95] Guo Z , Yuan Y , Chen C , Lin J , Ma Q , Liu G , Gao Y , Huang Y , Chen L , Chen LZ , Huang YF , Wang H , Li B , Chen Y , Zhang X . Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer. NPJ Precis Oncol 2022; 6(1): 34

[96] Capuozzo M , Picone C , Sabbatino F , Santorsola M , Caraglia F , Iervolino D , Sirica R , Gualillo O , Di Mauro G , Castiello R , Ianniello M , Cossu AM , Nebbioso A , Altucci L , Izzo F , Patrone R , Belli A , Berretta M , Cascella M , Perri F , Carratù AC , Nasti G , Di Maio M , Giordano A , Savarese G , Caraglia M , Ottaiano A . Genetic, epidemiological, clinical, and therapeutic trajectories in colon and rectal cancers. Cancers (Basel) 2025; 17(21): 3438

[97] Le DT , Uram JN , Wang H , Bartlett BR , Kemberling H , Eyring AD , Skora AD , Luber BS , Azad NS , Laheru D , Biedrzycki B , Donehower RC , Zaheer A , Fisher GA , Crocenzi TS , Lee JJ , Duffy SM , Goldberg RM , de la Chapelle A , Koshiji M , Bhaijee F , Huebner T , Hruban RH , Wood LD , Cuka N , Pardoll DM , Papadopoulos N , Kinzler KW , Zhou S , Cornish TC , Taube JM , Anders RA , Eshleman JR , Vogelstein B , Diaz LA Jr . PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372(26): 2509–2520

[98] Palmer CD , Rappaport AR , Davis MJ , Hart MG , Scallan CD , Hong SJ , Gitlin L , Kraemer LD , Kounlavouth S , Yang A , Smith L , Schenk D , Skoberne M , Taquechel K , Marrali M , Jaroslavsky JR , Nganje CN , Maloney E , Zhou R , Navarro-Gomez D , Greene AC , Grotenbreg G , Greer R , Blair W , Cao MD , Chan S , Bae K , Spira AI , Roychowdhury S , Carbone DP , Henick BS , Drake CG , Solomon BJ , Ahn DH , Mahipal A , Maron SB , Johnson B , Rousseau R , Yelensky R , Liao CY , Catenacci DVT , Allen A , Ferguson AR , Jooss K . Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med 2022; 28(8): 1619–1629

[99] Hecht JR , Spira AI , Nguyen AV , Berim LD , Starodub A , Pelster M , Gallinson D , Kasi A , Reilley M , Pimentel A , Chung KY , Lee F , Chauder B , Bae K , Schneck D , Allen AR , Jooss K , Ferguson AR , Beck JT . A randomized phase 2 study of an individualized neoantigen-targeting immunotherapy in patients with newly diagnosed metastatic microsatellite stable colorectal cancer (MSS-CRC). J Clin Oncol 2025; 43(Suppl 4): LBA13

[100] Yu YJ , Shan N , Li LY , Zhu YS , Lin LM , Mao CC , Hu TT , Xue XY , Su XP , Shen X , Cai ZZ . Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer. Cancer Immunol Immunother 2023; 72(7): 2045–2056

[101] Kale SR , Karande G , Gudur A , Garud A , Patil MS , Patil S . Recent trends in liver cancer: epidemiology, risk factors, and diagnostic techniques. Cureus 2024; 16(10): e72239

[102] Sung H , Ferlay J , Siegel RL , Laversanne M , Soerjomataram I , Jemal A , Bray F . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209–249

[103] Rumgay H , Arnold M , Ferlay J , Lesi O , Cabasag CJ , Vignat J , Laversanne M , McGlynn KA , Soerjomataram I . Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol 2022; 77(6): 1598–1606

[104] Llovet JM , Kelley RK , Villanueva A , Singal AG , Pikarsky E , Roayaie S , Lencioni R , Koike K , Zucman-Rossi J , Finn RS . Hepatocellular carcinoma. Nat Rev Dis Primers 2021; 7(1): 7

[105] Qin S , Kudo M , Meyer T , Bai Y , Guo Y , Meng Z , Satoh T , Marino D , Assenat E , Li S , Chen Y , Boisserie F , Abdrashitov R , Finn RS , Vogel A , Zhu AX . Tislelizumab vs. sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial. JAMA Oncol 2023; 9(12): 1651–1659

[106] Zhu AX , Finn RS , Edeline J , Cattan S , Ogasawara S , Palmer D , Verslype C , Zagonel V , Fartoux L , Vogel A , Sarker D , Verset G , Chan SL , Knox J , Daniele B , Webber AL , Ebbinghaus SW , Ma J , Siegel AB , Cheng AL , Kudo M , Alistar A , Asselah J , Blanc JF , Borbath I , Cannon T , Chung K , Cohn A , Cosgrove DP , Damjanov N , Gupta M , Karino Y , Karwal M , Kaubisch A , Kelley R , Van Laethem JL , Larson T , Lee J , Li D , Manhas A , Manji GA , Numata K , Parsons B , Paulson AS , Pinto C , Ramirez R , Ratnam S , Rizell M , Rosmorduc O , Sada Y , Sasaki Y , Stal PI , Strasser S , Trojan J , Vaccaro G , Van Vlierberghe H , Weiss A , Weiss KH , Yamashita T . Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018; 19(7): 940–952

[107] Finn RS , Ryoo BY , Merle P , Kudo M , Bouattour M , Lim HY , Breder V , Edeline J , Chao Y , Ogasawara S , Yau T , Garrido M , Chan SL , Knox J , Daniele B , Ebbinghaus SW , Chen E , Siegel AB , Zhu AX , Cheng AL . Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol 2020; 38(3): 193–202

[108] El-Khoueiry AB , Sangro B , Yau T , Crocenzi TS , Kudo M , Hsu C , Kim TY , Choo SP , Trojan J , Welling THR 3rd , Meyer T , Kang YK , Yeo W , Chopra A , Anderson J , Dela Cruz C , Lang L , Neely J , Tang H , Dastani HB , Melero I . Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017; 389(10088): 2492–2502

[109] Yau T , Park JW , Finn RS , Cheng AL , Mathurin P , Edeline J , Kudo M , Harding JJ , Merle P , Rosmorduc O , Wyrwicz L , Schott E , Choo SP , Kelley RK , Sieghart W , Assenat E , Zaucha R , Furuse J , Abou-Alfa GK , El-Khoueiry AB , Melero I , Begic D , Chen G , Neely J , Wisniewski T , Tschaika M , Sangro B . Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2022; 23(1): 77–90

[110] Liu JKH , Irvine AF , Jones RL , Samson A . Immunotherapies for hepatocellular carcinoma. Cancer Med 2022; 11(3): 571–591

[111] Chalmers ZR , Connelly CF , Fabrizio D , Gay L , Ali SM , Ennis R , Schrock A , Campbell B , Shlien A , Chmielecki J , Huang F , He Y , Sun J , Tabori U , Kennedy M , Lieber DS , Roels S , White J , Otto GA , Ross JS , Garraway L , Miller VA , Stephens PJ , Frampton GM . Analysis of 100 000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 2017; 9(1): 34

[112] Yarchoan M , Gane EJ , Marron TU , Perales-Linares R , Yan J , Cooch N , Shu DH , Fertig EJ , Kagohara LT , Bartha G , Northcott J , Lyle J , Rochestie S , Peters J , Connor JT , Jaffee EM , Csiki I , Weiner DB , Perales-Puchalt A , Sardesai NY . Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial. Nat Med 2024; 30(4): 1044–1053

[113] Cai Z , Su X , Qiu L , Li Z , Li X , Dong X , Wei F , Zhou Y , Luo L , Chen G , Chen H , Wang Y , Zeng Y , Liu X . Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion. Mol Cancer 2021; 20(1): 164

[114] Peng S , Chen S , Hu W , Mei J , Zeng X , Su T , Wang W , Chen Z , Xiao H , Zhou Q , Li B , Xie Y , Hu H , He M , Han Y , Tang L , Ma Y , Li X , Zhou X , Dai Z , Liu Z , Tan J , Xu L , Li S , Shen S , Li D , Lai J , Peng B , Peng Z , Kuang M . Combination neoantigen-based dendritic cell vaccination and adoptive T-cell transfer induces antitumor responses against recurrence of hepatocellular carcinoma. Cancer Immunol Res 2022; 10(6): 728–744

[115] Wu Q , Li Q. . A pilot trial of personalized neoantigen pulsed autologous dendritic cell vaccine as adjuvant treatment in hepatocellular carcinoma.. J Clin Oncol 2024; 42(Suppl 16): e16264

[116] Stoop TF , Javed AA , Oba A , Koerkamp BG , Seufferlein T , Wilmink JW , Besselink MG . Pancreatic cancer. Lancet 2025; 405(10485): 1182–1202

[117] Klein AP . Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol 2021; 18(7): 493–502

[118] Siegel RL , Kratzer TB , Giaquinto AN , Sung H , Jemal A . Cancer statistics, 2025. CA Cancer J Clin 2025; 75(1): 10–45

[119] Conroy T , Desseigne F , Ychou M , Bouché O , Guimbaud R , Bécouarn Y , Adenis A , Raoul JL , Gourgou-Bourgade S , de la Fouchardière C , Bennouna J , Bachet JB , Khemissa-Akouz F , Péré-Vergé D , Delbaldo C , Assenat E , Chauffert B , Michel P , Montoto-Grillot C , Ducreux M . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364(19): 1817–1825

[120] Chen Z , Zhang S , Han N , Jiang J , Xu Y , Ma D , Lu L , Guo X , Qiu M , Huang Q , Wang H , Mo F , Chen S , Yang L . A neoantigen-based peptide vaccine for patients with advanced pancreatic cancer refractory to standard treatment. Front Immunol 2021; 12: 691605

[121] Banales JM , Marin JJG , Lamarca A , Rodrigues PM , Khan SA , Roberts LR , Cardinale V , Carpino G , Andersen JB , Braconi C , Calvisi DF , Perugorria MJ , Fabris L , Boulter L , Macias RIR , Gaudio E , Alvaro D , Gradilone SA , Strazzabosco M , Marzioni M , Coulouarn C , Fouassier L , Raggi C , Invernizzi P , Mertens JC , Moncsek A , Ilyas SI , Heimbach J , Koerkamp BG , Bruix J , Forner A , Bridgewater J , Valle JW , Gores GJ . Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 2020; 17(9): 557–588

[122] Razumilava N , Gores GJ . Cholangiocarcinoma. Lancet 2014; 383(9935): 2168–2179

[123] Ilyas SI , Khan SA , Hallemeier CL , Kelley RK , Gores GJ . Cholangiocarcinoma—evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 2018; 15(2): 95–111

[124] Huang X , Tang T , Zhang G , Liang T . Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development. Mol Cancer 2021; 20(1): 50

[125] Abou-Alfa GK , Sahai V , Hollebecque A , Vaccaro G , Melisi D , Al-Rajabi R , Paulson AS , Borad MJ , Gallinson D , Murphy AG , Oh DY , Dotan E , Catenacci DV , Van Cutsem E , Ji T , Lihou CF , Zhen H , Féliz L , Vogel A . Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020; 21(5): 671–684

[126] Oh DY , He AR , Bouattour M , Okusaka T , Qin S , Chen LT , Kitano M , Lee CK , Kim JW , Chen MH , Suksombooncharoen T , Ikeda M , Lee MA , Chen JS , Potemski P , Burris HA 3rd , Ostwal V , Tanasanvimon S , Morizane C , Zaucha RE , McNamara MG , Avallone A , Cundom JE , Breder V , Tan B , Shimizu S , Tougeron D , Evesque L , Petrova M , Zhen DB , Gillmore R , Gupta VG , Dayyani F , Park JO , Buchschacher GL Jr , Rey F , Kim H , Wang J , Morgan C , Rokutanda N , Żotkiewicz M , Vogel A , Valle JW . Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol 2024; 9(8): 694–704

[127] Chen R , Zheng D , Li Q , Xu S , Ye C , Jiang Q , Yan F , Jia Y , Zhang X , Ruan J . Immunotherapy of cholangiocarcinoma: therapeutic strategies and predictive biomarkers. Cancer Lett 2022; 546: 215853

[128] Fang Y , Mo F , Shou J , Wang H , Luo K , Zhang S , Han N , Li H , Ye S , Zhou Z , Chen R , Chen L , Liu L , Wang H , Pan H , Chen S . A pan-cancer clinical study of personalized neoantigen vaccine monotherapy in treating patients with various types of advanced solid tumors. Clin Cancer Res 2020; 26(17): 4511–4520

[129] Zhu S , Liu C , Jin Y , Zhang H , Zhou M , Xu C , Shao J , Liu Q , Wei J , Shen J , Liu B . An advanced intrahepatic cholangiocarcinoma patient benefits from personalized immunotherapy. Inflammation 2024; 47(5): 1699–1705

[130] Janjigian YY , Cecchini M , Shitara K , Enzinger PC , Wainberg ZA , Chau I , Satoh T , Lee J , Nebozhyn M , Loboda A , Kobie J , Vajdi A , Shih CS , Cristescu R , Cao ZA . Genomic landscape of late-stage gastric cancer: analysis from KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 studies. JCO Precis Oncol 2025; 9(9): e2400456

[131] Goloudina A , Le Chevalier F , Authié P , Charneau P , Majlessi L . Shared neoantigens for cancer immunotherapy. Mol Ther Oncol 2025; 33(2): 200978

[132] Singhal A , Li BT , O’Reilly EM . Targeting KRAS in cancer. Nat Med 2024; 30(4): 969–983

[133] Punekar SR , Velcheti V , Neel BG , Wong KK . The current state of the art and future trends in RAS-targeted cancer therapies. Nat Rev Clin Oncol 2022; 19(10): 637–655

[134] Pant S , Wainberg ZA , Weekes CD , Furqan M , Kasi PM , Devoe CE , Leal AD , Chung V , Basturk O , VanWyk H , Tavares AM , Seenappa LM , Perry JR , Kheoh T , McNeil LK , Welkowsky E , DeMuth PC , Haqq CM , O’Reilly EM . Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat Med 2024; 30(2): 531–542

[135] Rappaport AR , Kyi C , Lane M , Hart MG , Johnson ML , Henick BS , Liao CY , Mahipal A , Shergill A , Spira AI , Goldman JW , Scallan CD , Schenk D , Palmer CD , Davis MJ , Kounlavouth S , Kemp L , Yang A , Li YJ , Likes M , Shen A , Boucher GR , Egorova M , Veres RL , Espinosa JA , Jaroslavsky JR , Kraemer Tardif LD , Acrebuche L , Puccia C , Sousa L , Zhou R , Bae K , Hecht JR , Carbone DP , Johnson B , Allen A , Ferguson AR , Jooss K . A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med 2024; 30(4): 1013–1022

[136] Verma V , Shrimali RK , Ahmad S , Dai W , Wang H , Lu S , Nandre R , Gaur P , Lopez J , Sade-Feldman M , Yizhak K , Bjorgaard SL , Flaherty KT , Wargo JA , Boland GM , Sullivan RJ , Getz G , Hammond SA , Tan M , Qi J , Wong P , Merghoub T , Wolchok J , Hacohen N , Janik JE , Mkrtichyan M , Gupta S , Khleif SN . PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1⁺CD38^hi cells and anti-PD-1 resistance. Nat Immunol 2019; 20(9): 1231–1243

[137] Xin K , Wei X , Shao J , Chen F , Liu Q , Liu B . Establishment of a novel tumor neoantigen prediction tool for personalized vaccine design. Hum Vaccin Immunother 2024; 20(1): 2300881

[138] Wells DK , van Buuren MM , Dang KK , Hubbard-Lucey VM , Sheehan KCF , Campbell KM , Lamb A , Ward JP , Sidney J , Blazquez AB , Rech AJ , Zaretsky JM , Comin-Anduix B , Ng AHC , Chour W , Yu TV , Rizvi H , Chen JM , Manning P , Steiner GM , Doan XC , The Tumor Neoantigen Selection Alliance , Merghoub T , Guinney J , Kolom A , Selinsky C , Ribas A , Hellmann MD , Hacohen N , Sette A , Heath JR , Bhardwaj N , Ramsdell F , Schreiber RD , Schumacher TN , Kvistborg P , Defranoux NA. . Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction.. Cell 2020; 183(3): 818–34

[139] Hundal J , Kiwala S , McMichael J , Miller CA , Xia H , Wollam AT , Liu CJ , Zhao S , Feng YY , Graubert AP , Wollam AZ , Neichin J , Neveau M , Walker J , Gillanders WE , Mardis ER , Griffith OL , Griffith M . pVACtools: a computational toolkit to identify and visualize cancer neoantigens. Cancer Immunol Res 2020; 8(3): 409–420

[140] Müller M , Huber F , Arnaud M , Kraemer AI , Altimiras ER , Michaux J , Taillandier-Coindard M , Chiffelle J , Murgues B , Gehret T , Auger A , Stevenson BJ , Coukos G , Harari A , Bassani-Sternberg M. . Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction.. Immunity 2023; 56(11): 2650–63

[141] Kumar A , Dixit S , Srinivasan K , Dinakaran M , Durai Raj Vincent PM . Personalized cancer vaccine design using AI-powered technologies. Front Immunol 2024; 15: 1357217

[142] Ouspenskaia T , Law T , Clauser KR , Klaeger S , Sarkizova S , Aguet F , Li B , Christian E , Knisbacher BA , Le PM , Hartigan CR , Keshishian H , Apffel A , Oliveira G , Zhang W , Chen S , Chow YT , Ji Z , Jungreis I , Shukla SA , Justesen S , Bachireddy P , Kellis M , Getz G , Hacohen N , Keskin DB , Carr SA , Wu CJ , Regev A . Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer. Nat Biotechnol 2022; 40(2): 209–217

[143] Bassani-Sternberg M , Bräunlein E , Klar R , Engleitner T , Sinitcyn P , Audehm S , Straub M , Weber J , Slotta-Huspenina J , Specht K , Martignoni ME , Werner A , Hein R , Busch DH , Peschel C , Rad R , Cox J , Mann M , Krackhardt AM . Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun 2016; 7: 13404

[144] Cai Y , Gong M , Zeng M , Leng F , Lv D , Guo J , Wang H , Li Y , Lin Q , Jing J , Zhang Y , Xu J , Li Y . Immunopeptidomics-guided discovery and characterization of neoantigens for personalized cancer immunotherapy. Sci Adv 2025; 11(21): eadv6445

[145] Zhang Y , Chen TT , Li X , Lan AL , Ji PF , Zhu YJ , Ma XY . Advances and challenges in neoantigen prediction for cancer immunotherapy. Front Immunol 2025; 16: 1617654

[146] Zhang X , Qi Y , Zhang Q , Liu W . Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy. Biomed Pharmacother 2019; 120: 109542

[147] Chen R , Fulton KM , Twine SM , Li J . Identification of MHC peptides using mass spectrometry for neoantigen discovery and cancer vaccine development. Mass Spectrom Rev 2021; 40(2): 110–125

[148] Abbosh C , Birkbak NJ , Wilson GA , Jamal-Hanjani M , Constantin T , Salari R , Le Quesne J , Moore DA , Veeriah S , Rosenthal R , Marafioti T , Kirkizlar E , Watkins TBK , McGranahan N , Ward S , Martinson L , Riley J , Fraioli F , Al Bakir M , Grönroos E , Zambrana F , Endozo R , Bi WL , Fennessy FM , Sponer N , Johnson D , Laycock J , Shafi S , Czyzewska-Khan J , Rowan A , Chambers T , Matthews N , Turajlic S , Hiley C , Lee SM , Forster MD , Ahmad T , Falzon M , Borg E , Lawrence D , Hayward M , Kolvekar S , Panagiotopoulos N , Janes SM , Thakrar R , Ahmed A , Blackhall F , Summers Y , Hafez D , Naik A , Ganguly A , Kareht S , Shah R , Joseph L , Marie Quinn A , Crosbie PA , Naidu B , Middleton G , Langman G , Trotter S , Nicolson M , Remmen H , Kerr K , Chetty M , Gomersall L , Fennell DA , Nakas A , Rathinam S , Anand G , Khan S , Russell P , Ezhil V , Ismail B , Irvin-Sellers M , Prakash V , Lester JF , Kornaszewska M , Attanoos R , Adams H , Davies H , Oukrif D , Akarca AU , Hartley JA , Lowe HL , Lock S , Iles N , Bell H , Ngai Y , Elgar G , Szallasi Z , Schwarz RF , Herrero J , Stewart A , Quezada SA , Peggs KS , Van Loo P , Dive C , Lin CJ , Rabinowitz M , Aerts H , Hackshaw A , Shaw JA , Zimmermann BG , Swanton C . Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 2017; 545(7655): 446–451

[149] Xu J , Liao K , Yang X , Wu C , Wu W . Using single-cell sequencing technology to detect circulating tumor cells in solid tumors. Mol Cancer 2021; 20(1): 104

[150] Rota M , Torresan I , Palmerio S , Tasselli E , Rossi A , Zivi A , Zacchi F . The role of therapeutic cancer vaccines in the modern immunotherapy era: state of the art with recent progress and future challenges. Crit Rev Oncol Hematol 2026; 217: 105068

[151] Detrés Román CR , Erwin MM , Rudloff MW , Revetta F , Murray KA , Favret NR , Roetman JJ , Roland JT , Washington MK , Philip M . Vaccination generates functional progenitor tumor-specific CD8 T cells and long-term tumor control. J Immunother Cancer 2024; 12(10): e009129

[152] Ventin M , Cattaneo G , Maggs L , Arya S , Wang X , Ferrone CR . Implications of high tumor burden on chimeric antigen receptor T-cell immunotherapy: a review. JAMA Oncol 2024; 10(1): 115–121

[153] Wang X , Huang Z , Xing L , Shang L , Jiang J , Deng C , Yu W , Peng L , Yang H , Zheng X , Liu X , Yang H , Chen Y , Li Y , Liu J , Xie X , Xu W , Xia X , Liu Z , Liu W , Jiang S , Zeng Y , Lu L , Wang J . STING agonist-based ER-targeting molecules boost antigen cross-presentation. Nature 2025; 641(8061): 202–210

[154] Ott PA , Hu Z , Keskin DB , Shukla SA , Sun J , Bozym DJ , Zhang W , Luoma A , Giobbie-Hurder A , Peter L , Chen C , Olive O , Carter TA , Li S , Lieb DJ , Eisenhaure T , Gjini E , Stevens J , Lane WJ , Javeri I , Nellaiappan K , Salazar AM , Daley H , Seaman M , Buchbinder EI , Yoon CH , Harden M , Lennon N , Gabriel S , Rodig SJ , Barouch DH , Aster JC , Getz G , Wucherpfennig K , Neuberg D , Ritz J , Lander ES , Fritsch EF , Hacohen N , Wu CJ . An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017; 547(7662): 217–221

[155] Li WH , Li YM . Chemical strategies to boost cancer vaccines. Chem Rev 2020; 120(20): 11420–11478

[156] Butt AQ , Mills KH . Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene 2014; 33(38): 4623–4631

[157] Ding Z , Li Q , Zhang R , Xie L , Shu Y , Gao S , Wang P , Su X , Qin Y , Wang Y , Fang J , Zhu Z , Xia X , Wei G , Wang H , Qian H , Guo X , Gao Z , Wang Y , Wei Y , Xu Q , Xu H , Yang L . Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal Transduct Target Ther 2021; 6(1): 26

[158] Liao JY , Zhang S . Safety and efficacy of personalized cancer vaccines in combination with immune checkpoint inhibitors in cancer treatment. Front Oncol 2021; 11: 663264

[159] Horn LA , Fousek K , Hamilton DH , Hodge JW , Zebala JA , Maeda DY , Schlom J , Palena C . Vaccine increases the diversity and activation of intratumoral T cells in the context of combination immunotherapy. Cancers (Basel) 2021; 13(5): 968

[160] Salvatori E , Lione L , Compagnone M , Pinto E , Conforti A , Ciliberto G , Aurisicchio L , Palombo F . Neoantigen cancer vaccine augments anti-CTLA-4 efficacy. NPJ Vaccines 2022; 7(1): 15

[161] Sahin U , Oehm P , Derhovanessian E , Jabulowsky RA , Vormehr M , Gold M , Maurus D , Schwarck-Kokarakis D , Kuhn AN , Omokoko T , Kranz LM , Diken M , Kreiter S , Haas H , Attig S , Rae R , Cuk K , Kemmer-Brück A , Breitkreuz A , Tolliver C , Caspar J , Quinkhardt J , Hebich L , Stein M , Hohberger A , Vogler I , Liebig I , Renken S , Sikorski J , Leierer M , Müller V , Mitzel-Rink H , Miederer M , Huber C , Grabbe S , Utikal J , Pinter A , Kaufmann R , Hassel JC , Loquai C , Türeci Ö . An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 2020; 585(7823): 107–112

[162] Jing N , Wang L , Zhuang H , Jiang G , Liu Z . Enhancing therapeutic effects of murine cancer vaccine by reshaping gut microbiota with Lactobacillus rhamnosus GG and jujube powder. Front Immunol 2023; 14: 1195075

[163] Tomasi M , Dalsass M , Beghini F , Zanella I , Caproni E , Fantappiè L , Gagliardi A , Irene C , König E , Frattini L , Masetti G , Isaac SJ , Armanini F , Cumbo F , Blanco-Míguez A , Grandi A , Segata N , Grandi G . Commensal Bifidobacterium strains enhance the efficacy of neo-epitope based cancer vaccines. Vaccines (Basel) 2021; 9(11): 1356

[164] Fu R , Qi R , Xiong H , Lei X , Jiang Y , He J , Chen F , Zhang L , Qiu D , Chen Y , Nie M , Guo X , Zhu Y , Zhang J , Yue M , Cao J , Wang G , Que Y , Fang M , Wang Y , Chen Y , Cheng T , Ge S , Zhang J , Yuan Q , Zhang T , Xia N . Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects. Signal Transduct Target Ther 2024; 9(1): 118

[165] Zhao J , Chen Y , Ding ZY , Liu JY . Safety and efficacy of therapeutic cancer vaccines alone or in combination with immune checkpoint inhibitors in cancer treatment. Front Pharmacol 2019; 10: 1184

[166] Keskin DB , Anandappa AJ , Sun J , Tirosh I , Mathewson ND , Li S , Oliveira G , Giobbie-Hurder A , Felt K , Gjini E , Shukla SA , Hu Z , Li L , Le PM , Allesøe RL , Richman AR , Kowalczyk MS , Abdelrahman S , Geduldig JE , Charbonneau S , Pelton K , Iorgulescu JB , Elagina L , Zhang W , Olive O , McCluskey C , Olsen LR , Stevens J , Lane WJ , Salazar AM , Daley H , Wen PY , Chiocca EA , Harden M , Lennon NJ , Gabriel S , Getz G , Lander ES , Regev A , Ritz J , Neuberg D , Rodig SJ , Ligon KL , Suvà ML , Wucherpfennig KW , Hacohen N , Fritsch EF , Livak KJ , Ott PA , Wu CJ , Reardon DA . Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 2019; 565(7738): 234–239

[167] Turajlic S , Sottoriva A , Graham T , Swanton C . Resolving genetic heterogeneity in cancer. Nat Rev Genet 2019; 20(7): 404–416

[168] McGranahan N , Furness AJ , Rosenthal R , Ramskov S , Lyngaa R , Saini SK , Jamal-Hanjani M , Wilson GA , Birkbak NJ , Hiley CT , Watkins TB , Shafi S , Murugaesu N , Mitter R , Akarca AU , Linares J , Marafioti T , Henry JY , Van Allen EM , Miao D , Schilling B , Schadendorf D , Garraway LA , Makarov V , Rizvi NA , Snyder A , Hellmann MD , Merghoub T , Wolchok JD , Shukla SA , Wu CJ , Peggs KS , Chan TA , Hadrup SR , Quezada SA , Swanton C . Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016; 351(6280): 1463–1469

[169] Anagnostou V , Smith KN , Forde PM , Niknafs N , Bhattacharya R , White J , Zhang T , Adleff V , Phallen J , Wali N , Hruban C , Guthrie VB , Rodgers K , Naidoo J , Kang H , Sharfman W , Georgiades C , Verde F , Illei P , Li QK , Gabrielson E , Brock MV , Zahnow CA , Baylin SB , Scharpf RB , Brahmer JR , Karchin R , Pardoll DM , Velculescu VE . Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov 2017; 7(3): 264–276

[170] Lin Q , Wei Y , Xu G , Wang L , Ling F , Chen X , Cheng Y , Zhou Y . Integrative multi-omic profiling of the neoantigen landscape of glioblastoma for the development of therapeutic vaccines reveals vast heterogeneity in immunogenic signatures. Front Oncol 2025; 15: 1507632

[171] Schaettler MO , Desai R , Wang AZ , Livingstone AJ , Kobayashi DK , Coxon AT , Bowman-Kirigin JA , Liu CJ , Li M , Bender DE , White MJ , Kranz DM , Johanns TM , Dunn GP . TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma. J Immunother Cancer 2023; 11(2): e006121

[172] Chen F , Zou Z , Du J , Su S , Shao J , Meng F , Yang J , Xu Q , Ding N , Yang Y , Liu Q , Wang Q , Sun Z , Zhou S , Du S , Wei J , Liu B . Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. J Clin Invest 2019; 129(5): 2056–2070

[173] Erdogdu IH . MHC class 1 and PDL-1 status of primary tumor and lymph node metastatic tumor tissue in gastric cancers. Gastroenterol Res Pract 2019; 2019: 4785098

[174] McGranahan N , Swanton C . Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 2017; 168(4): 613–628

[175] Reiter JG , Makohon-Moore AP , Gerold JM , Heyde A , Attiyeh MA , Kohutek ZA , Tokheim CJ , Brown A , DeBlasio RM , Niyazov J , Zucker A , Karchin R , Kinzler KW , Iacobuzio-Donahue CA , Vogelstein B , Nowak MA . Minimal functional driver gene heterogeneity among untreated metastases. Science 2018; 361(6406): 1033–1037

[176] Parikh AR , Leshchiner I , Elagina L , Goyal L , Levovitz C , Siravegna G , Livitz D , Rhrissorrakrai K , Martin EE , Van Seventer EE , Hanna M , Slowik K , Utro F , Pinto CJ , Wong A , Danysh BP , de la Cruz FF , Fetter IJ , Nadres B , Shahzade HA , Allen JN , Blaszkowsky LS , Clark JW , Giantonio B , Murphy JE , Nipp RD , Roeland E , Ryan DP , Weekes CD , Kwak EL , Faris JE , Wo JY , Aguet F , Dey-Guha I , Hazar-Rethinam M , Dias-Santagata D , Ting DT , Zhu AX , Hong TS , Golub TR , Iafrate AJ , Adalsteinsson VA , Bardelli A , Parida L , Juric D , Getz G , Corcoran RB . Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med 2019; 25(9): 1415–1421

[177] Maddipati R . Metastatic heterogeneity in pancreatic cancer: mechanisms and opportunities for targeted intervention. J Clin Invest 2025; 135(14): e191943

[178] Chen J , Wu Q , Berglund AE , Macaulay RJ , Mulé JJ , Etame AB . Tumor-associated macrophages in glioblastoma: mechanisms of tumor progression and therapeutic strategies. Cells 2025; 14(18): 1458

[179] Sahin U , Derhovanessian E , Miller M , Kloke BP , Simon P , Löwer M , Bukur V , Tadmor AD , Luxemburger U , Schrörs B , Omokoko T , Vormehr M , Albrecht C , Paruzynski A , Kuhn AN , Buck J , Heesch S , Schreeb KH , Müller F , Ortseifer I , Vogler I , Godehardt E , Attig S , Rae R , Breitkreuz A , Tolliver C , Suchan M , Martic G , Hohberger A , Sorn P , Diekmann J , Ciesla J , Waksmann O , Brück AK , Witt M , Zillgen M , Rothermel A , Kasemann B , Langer D , Bolte S , Diken M , Kreiter S , Nemecek R , Gebhardt C , Grabbe S , Höller C , Utikal J , Huber C , Loquai C , Türeci Ö . Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 2017; 547(7662): 222–226

[180] Rosenthal R , Cadieux EL , Salgado R , Bakir MA , Moore DA , Hiley CT , Lund T , Tanić M , Reading JL , Joshi K , Henry JY , Ghorani E , Wilson GA , Birkbak NJ , Jamal-Hanjani M , Veeriah S , Szallasi Z , Loi S , Hellmann MD , Feber A , Chain B , Herrero J , Quezada SA , Demeulemeester J , Van Loo P , Beck S , McGranahan N , Swanton C . Neoantigen-directed immune escape in lung cancer evolution. Nature 2019; 567(7749): 479–485

[181] Xu X , Zhou Z , Li H , Fan Y . Towards customized cancer vaccines: a promising filed in personalized cancer medicine. Expert Rev Vaccines 2021; 20(5): 545–557

[182] Perrinjaquet M , Richard Schlegel C . Personalized neoantigen cancer vaccines: an analysis of the clinical and commercial potential of ongoing development programs. Drug Discov Today 2023; 28(11): 103773

[183] Martini DJ , Wu CJ . The future of personalized cancer vaccines. Cancer Discov 2025; 15(7): 1315–1324

[184] Wang C , Shi Y , Zhang D , Sun Y , Xie J , Wu B , Zhang C , Liu X . Generalization of neoantigen-based tumor vaccine by delivering peptide-MHC complex via oncolytic virus. EMBO Mol Med 2025; 17(5): 1118–1152

[185] Magoola M , Niazi SK . Engineering universal cancer immunity: non-tumor-specific mRNA vaccines trigger epitope spreading in cold tumors. Vaccines (Basel) 2025; 13(9): 970

[186] Anan M , Del Maestro RF , Hata N , Fujiki M . O⁶-methylguanine methyltransferase promoter methylation status of glioblastoma cell line clonal population. Neuropathology 2024; 44(1): 41–46

[187] Zhang C , Zhang J , Xu FP , Wang YG , Xie Z , Su J , Dong S , Nie Q , Shao Y , Zhou Q , Yang JJ , Yang XN , Zhang XC , Li Z , Wu YL , Zhong WZ . Genomic landscape and immune microenvironment features of preinvasive and early invasive lung adenocarcinoma. J Thorac Oncol 2019; 14(11): 1912–1923

[188] Martínez-Jiménez F , Muiños F , Sentís I , Deu-Pons J , Reyes-Salazar I , Arnedo-Pac C , Mularoni L , Pich O , Bonet J , Kranas H , Gonzalez-Perez A , Lopez-Bigas N . A compendium of mutational cancer driver genes. Nat Rev Cancer 2020; 20(10): 555–572

[189] Varghese AM , Perry MA , Chou JF , Nandakumar S , Muldoon D , Erakky A , Zucker A , Fong C , Mehine M , Nguyen B , Basturk O , Balogun F , Kelsen DP , Brannon AR , Mandelker D , Vakiani E , Park W , Yu KH , Stadler ZK , Schattner MA , Jarnagin WR , Wei AC , Chakravarty D , Capanu M , Schultz N , Berger MF , Iacobuzio-Donahue CA , Bandlamudi C , O’Reilly EM . Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Nat Med 2025; 31(2): 466–477

[190] Wainberg ZA , Weekes CD , Furqan M , Kasi PM , Devoe CE , Leal AD , Chung V , Perry JR , Kheoh T , McNeil LK , Welkowsky E , DeMuth PC , Haqq CM , Pant S , O’Reilly EM . Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. Nat Med 2025; 31(11): 3648–3653

[191] Nusrat F , Khanna A , Jain A , Jiang W , Lavu H , Yeo CJ , Bowne W , Nevler A . The clinical implications of KRAS mutations and variant allele frequencies in pancreatic ductal adenocarcinoma. J Clin Med 2024; 13(7): 2103

[192] Akkapeddi P , Hattori T , Khan I , Glasser E , Koide A , Ketavarapu G , Whaby M , Zuberi M , Teng KW , Lefler J , Maso L , Bang I , Ostrowski MC , O’Bryan JP , Koide S . Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors. Proc Natl Acad Sci USA 2023; 120(28): e2302485120

[193] Witkiewicz AK , McMillan EA , Balaji U , Baek G , Lin WC , Mansour J , Mollaee M , Wagner KU , Koduru P , Yopp A , Choti MA , Yeo CJ , McCue P , White MA , Knudsen ES . Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun 2015; 6(1): 6744

[194] Merlotti A , Sadacca B , Arribas YA , Ngoma M , Burbage M , Goudot C , Houy A , Rocañín-Arjó A , Lalanne A , Seguin-Givelet A , Lefevre M , Heurtebise-Chrétien S , Baudon B , Oliveira G , Loew D , Carrascal M , Wu CJ , Lantz O , Stern MH , Girard N , Waterfall JJ , Amigorena S . Noncanonical splicing junctions between exons and transposable elements represent a source of immunogenic recurrent neo-antigens in patients with lung cancer. Sci Immunol 2023; 8(80): eabm6359

[195] Kwok DW , Okada H , Costello JF . Activating the dark genome to illuminate cancer vaccine targets. Nat Genet 2024; 56(9): 1770–1771

[196] Li Y , Zhang Y , Pan T , Zhou P , Zhou W , Gao Y , Zheng S , Xu J . Shedding light on the hidden human proteome expands immunopeptidome in cancer. Brief Bioinform 2022; 23(2): bbac034

[197] Laumont CM , Vincent K , Hesnard L , Audemard É , Bonneil É , Laverdure JP , Gendron P , Courcelles M , Hardy MP , Côté C , Durette C , St-Pierre C , Benhammadi M , Lanoix J , Vobecky S , Haddad E , Lemieux S , Thibault P , Perreault C . Noncoding regions are the main source of targetable tumor-specific antigens. Sci Transl Med 2018; 10(470): eaau5516

[198] Lu SX , De Neef E , Thomas JD , Sabio E , Rousseau B , Gigoux M , Knorr DA , Greenbaum B , Elhanati Y , Hogg SJ , Chow A , Ghosh A , Xie A , Zamarin D , Cui D , Erickson C , Singer M , Cho H , Wang E , Lu B , Durham BH , Shah H , Chowell D , Gabel AM , Shen Y , Liu J , Jin J , Rhodes MC , Taylor RE , Molina H , Wolchok JD , Merghoub T , Diaz LA Jr , Abdel-Wahab O , Bradley RK. . Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.. Cell 2021; 184(15): 4032–47

[199] Hao Q , Long Y , Yang Y , Deng Y , Ding Z , Yang L , Shu Y , Xu H . Development and clinical applications of therapeutic cancer vaccines with individualized and shared neoantigens. Vaccines (Basel) 2024; 12(7): 717

[200] Prabhu N , Rajinikanth V , Narayanan M . Neoantigen-driven cancer vaccines in personalized oncology: progress, obstacles, and translational prospects. Mol Biol Rep 2026; 53(1): 256

Rights & permissions

Higher Education Press